Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 94,028 shares changing hands.
Mateon Therapeutics Trading Up 9.1 %
The business has a 50-day moving average of $0.03 and a 200 day moving average of $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Technology Stocks Explained: Here’s What to Know About Tech
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- 3 Dividend Kings To Consider
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
